• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 29.37
  • VXN 2.82
  • VXO 33.70
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

Immunomedics, Inc. engages in the research, development, manufacture, and marketing of monoclonal antibody-based products for the treatment of cancer, and autoimmune and other serious diseases. Its products include epratuzumab, a Phase III clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkin?s lymphoma; Veltuzumab, a Phase I/II clinical study product for the treatment of patients with non-Hodgkin?s lymphoma, immune thrombocytopenic purpura, and chronic lymphocytic leukemia; Yttrium Y 90 Clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that is in Phase Ib clinical trail; and Yttrium Y 90 epratuzumab tetraxetan, a Phase I/II clinical study product for patients with non-Hodgkin?s lymphoma. The company?s preclinal trial products comprise Milatuzumab, a transmembrane protein product for antibody-drug immunoconjugate therapy; and Labetuzumab, a product candidate that targets colon, rectum, breast, lung, and other solid tumors. In addition, the company markets and sells a diagnostic product, ?LeukoScan?, which is used to treat infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. It also develops Dock-and-Lock method technology that combines conjugation chemistry and genetic engineering to enable the creation of novel human therapeutics, and the construction of enhanced recombinant products. The company distributes its products in the United States, Europe, and Japan. Immunomedics has a license and collaboration agreement with Nycomed GmbH to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications; and a partnership and cross-licensing agreement with Alexis Biotech Ltd. to develop vaccines against melanoma and chronic lymphocytic leukemia, and infectious diseases, such as AIDS. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.

NO
     
IMMU (Immunomedics Inc)
Last Trade 12.84 Date 3/28/2020
Change % -2.95 % Price Change -0.39
Open 12.88 52 Week High 0.0
High 13.57 52 Week Low 0.0
Low 12.62 Type stock
Volume 2328982 Average Volume 2129551
Prev Close 13.23 Stock Exchange NASDAQ
Bid 12.9 Ask 13.04
Bid Size 1 Ask Size 1
1st Yr Estimated EPS Growth -0.1196 2nd Yr Estimated EPS Growth -0.4444
2 Years Forward Earning Yield -0.0701 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 1.254 Book Value Yield 0.0977
Buy Back Yield CAPE Ratio
Cash Return -0.0787 Cash Flow per Share -1.1489
Cash Flow Yield -0.0895 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.1433 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue 51.0854 EV / Pre Tax Income
EV / Revenue 8143.5385 EV / Total Asset 3.5764
Expected Dividend Growth Rate Free Cash Flow per Share -1.1843
Free Caash Flow Ratio Free Cash Flow Yield -0.0922
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.1262 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 10.239486 PB Ratio 10 Year Growth 0.036471
PB Ratio 3 Year Growth 59.081111 Cash Ratio 3 Year Average 1105.3597
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 82.490691 PE Ratio 10 Year Growth
PE Ratio 10 Year High 367.0 PE Ratio 10 Year Low 5.836735
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 0.8025
Price to Cash Ratio 4.479702 Price / EBITDA
Price to Sales Ratio 8427.261966 Price to Sales Ratio 10 Year Growth 1.133405
Price to Sales Ratio 3 Year Avg 1474.910595 Price to Sales Ratio 5 Year Avg
Sale per Share 0.0015 Sales Yield 1.0E-4
Sustainable Growth Rate -1.3353 Tangible Book Value per Share 1.254
Tangible Book Value per Share 3 year Avg 0.5023 Tangible Book Value per Share 5 year Avg 0.1265
Total Asset per Share 3.1399 Total Yield
Working Capital per Share 2.6502 Working Capital per Share 3 Year Avg 1.3572
Working Capital per Share 5 Year Avg 1.0174 Beta 1.458153